Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Galecto, Inc. - Common Stock (NQ:GLTO)

9.450 -0.130 (-1.36%)
Streaming Delayed Price Updated: 10:12 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Galecto, Inc. - Common Stock

Peraso Inc. (NASDAQ: PRSO) Regains Nasdaq Compliance, Earns $2.74 Price Target from Intro-act – More Stocks Inside
Via AB Newswire
Galecto Inc. (NASDAQ: GLTO) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
From Galecto, Inc.
Via GlobeNewswire
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
From Galecto, Inc.
Via GlobeNewswire
Galecto to Participate in SVB Securities Global Biopharma Conference
From Galecto, Inc.
Via GlobeNewswire
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
From Galecto, Inc.
Via GlobeNewswire
Galecto Reports Third Quarter Operating and Financial Results
From Galecto, Inc.
Via GlobeNewswire
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
From Galecto, Inc.
Via GlobeNewswire
Galecto to Participate in Jefferies London Healthcare Conference
From Galecto, Inc.
Via GlobeNewswire
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
From Galecto, Inc.
Via GlobeNewswire
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor 
From Galecto, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.